Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1235 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-01
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 23.56 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 37.03 | Oscillator | Neutral |
| Williams %R (14) | -57.31 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.16 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 39.20 (+DI 15.9 / -DI 38.1) | Trend | Strong Sell |
| EMA 20 | 0.16 | MA | Strong Sell |
| SMA 20 | 0.07 | MA | Strong Sell |
| EMA 50 | 0.46 | MA | Strong Sell |
| SMA 50 | 0.55 | MA | Strong Sell |
| SMA 200 | 1.20 | MA | Strong Sell |
Current price $0.0739
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Apr 2, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 5, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 15, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 12, 25 | Mizuho | maintain | Neutral | Neutral |
| Aug 28, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 19, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 15, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 15, 25 | LUCID CAPITAL MARKETS | maintain | Buy | Buy |
| Jun 23, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | BTAI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -1.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.0x | EPS est. -2.70 | Elevated |
| Price / Book | -0.0x | 1.7x | Discount |
| Price / Sales | 3.1x | 340.8x | Discount |
| EV / EBITDA | -1.8x | -2.1x | Discount |
| Return on equity | 69.9% | — | Top tier |
| Gross margin | 45.3% | 36.6% | Above hist. |
| Debt / Equity | -0.90 | -0.56 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -46.97 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 12, 26 | Atkins Susan E. | director | A-Award | 17,000 @ $1.06 | $18.02K |
Stock news · updated daily
BioXcel Therapeutics (NASDAQ: BTAI - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of current
BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,124,886 shares, an increase of 84.8% from the August 15th total of 3,314,382 shares. Based on an average trading volume of 7,193,434 shares,
| Aug 12, 26 |
| Atkins Susan E. |
| director: |
| 0 |
| — |
| Jun 15, 26 | Rodriguez Javier | officer: See Remarks | M-Exempt | 35 | — |
| Jun 15, 26 | Rodriguez Javier | officer: See Remarks | M-Exempt | 35 | — |
| Jun 15, 26 | Steinhart Richard I | officer: Chief Financial Officer | M-Exempt | 35 | — |
| Jun 15, 26 | Steinhart Richard I | officer: Chief Financial Officer | M-Exempt | 35 | — |
| Jun 15, 26 | Yocca Frank | officer: Chief Scientific Officer | M-Exempt | 35 | — |
| Jun 15, 26 | Yocca Frank | officer: Chief Scientific Officer | M-Exempt | 35 | — |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.44 | -0.49 | Miss -11.4% | $182.0K |
| May 15, 2026 | -0.59 | -0.54 | Beat 8.5% | $206.0K |
| Mar 26, 2026 | -0.34 | -0.58 | Miss -70.6% | $256.0K |
| Nov 12, 2025 | -1.54 | -2.18 | Miss -41.6% | $98.00K |
| Aug 12, 2025 | -2.30 | -2.45 | Miss -6.5% | $120.0K |
| May 12, 2025 | -2.72 | -1.50 | Beat 44.9% | $168.0K |
| 4 | Aug 14, 2026 | 2026-08-14 19:00:43 | View |
| 3 | Aug 14, 2026 | 2026-08-14 19:00:05 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 10:04:39 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:31:06 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 07:00:24 | View |
| 8-K | Aug 3, 2026 | 2026-08-03 07:00:23 | View |
Proxy statement (DEF 14A) disclosures